Cite
APA Citation
She, L., Hu, H., Liao, M., Xia, X., Shi, Y., Yao, L., Ding, D., Zhu, Y., Zeng, S., Shen, L., Huang, J., & Carbone, D. P. (2019). cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. Lung cancer, 138, 88–94. http://access.bl.uk/ark:/81055/vdc_100098057611.0x000048